Adverse Changes. Since the date hereof, no event or series of events shall have occurred that has had or would reasonably be expected to have a Material Adverse Effect.
Appears in 50 contracts
Sources: Securities Purchase Agreement (Summit Therapeutics Inc.), Securities Purchase Agreement (Lexeo Therapeutics, Inc.), Stock Purchase Agreement (Zymeworks Inc.)
Adverse Changes. Since the date hereof, no event or series of events shall have occurred that that, individually or in the aggregate, has had or would reasonably be expected to have a Material Adverse Effect.
Appears in 6 contracts
Sources: Stock Purchase Agreement (Ventyx Biosciences, Inc.), Stock Purchase Agreement (Recursion Pharmaceuticals, Inc.), Stock Purchase Agreement (Recursion Pharmaceuticals, Inc.)
Adverse Changes. Since the date hereof, no event or series of events shall have occurred that has had or would reasonably be expected to have a Material Adverse Effect.
Appears in 3 contracts
Sources: Securities Purchase Agreement (Outset Medical, Inc.), Securities Purchase Agreement (Outset Medical, Inc.), Securities Purchase Agreement (Biodesix Inc)
Adverse Changes. Since the date hereof, no No event or series of events shall have occurred that has had or would reasonably be expected to have result in a Material Adverse Effect.; and
Appears in 2 contracts
Sources: Note Purchase Agreement (World Heart Corp), Note Purchase Agreement (Abiomed Inc)
Adverse Changes. Since the date hereof, no No event or series of events shall have occurred that has had or would reasonably be expected to have a Material Adverse Effect.
Appears in 2 contracts
Sources: Securities Purchase Agreement (Cyalume Technologies Holdings, Inc.), Securities Purchase Agreement (Cyalume Technologies Holdings, Inc.)
Adverse Changes. Since As of the date hereofClosing Date, no event or series of events shall have occurred that has had or would reasonably be expected to have a Material Adverse Effect.
Appears in 2 contracts
Sources: Securities Purchase Agreement (Puma Biotechnology, Inc.), Securities Purchase Agreement (Puma Biotechnology, Inc.)
Adverse Changes. Since the date hereof, no event or series of events shall have occurred that has had or would would, individually or in the aggregate, reasonably be expected to have a Material Adverse Effect.
Appears in 2 contracts
Sources: Securities Purchase Agreement (Heron Therapeutics, Inc. /De/), Securities Purchase Agreement (Rubric Capital Management LP)
Adverse Changes. Since the date hereof, no event or series of events shall which reasonably would have occurred that has had or would reasonably be expected to have result in a Material Adverse Effect.Effect shall have occurred;
Appears in 1 contract
Adverse Changes. Since the date hereof, no event or series of events shall have occurred that has had or would reasonably be expected likely to have a Material Adverse Effect.
Appears in 1 contract
Sources: Securities Purchase Agreement (Opus Genetics, Inc.)